文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Landscape of cancer cell therapies: trends and real-world data.

作者信息

Saez-Ibañez Ana Rosa, Upadhaya Samik, Partridge Tanya, Shah Monica, Correa Diego, Campbell Jay

出版信息

Nat Rev Drug Discov. 2022 Sep;21(9):631-632. doi: 10.1038/d41573-022-00095-1.

DOI:10.1038/d41573-022-00095-1
PMID:35650421
Abstract
摘要

相似文献

[1]
Landscape of cancer cell therapies: trends and real-world data.

Nat Rev Drug Discov. 2022-9

[2]
Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.

BMC Med. 2022-4-12

[3]
Practical Application of Real-World Evidence in Developing Cancer Therapies.

JCO Clin Cancer Inform. 2019-7

[4]
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.

BMC Cancer. 2022-3-10

[5]
Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.

Oncologist. 2018-1-9

[6]
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.

Oncologist. 2018-12-27

[7]
Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.

Cancer Med. 2019-10-24

[8]
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.

Cancer Treat Rev. 2020-5-16

[9]
Flatiron Health leverages expertise with real-world data to examine cancer care disparities.

Am J Manag Care. 2021-12

[10]
Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe.

Radiol Oncol. 2020-10-11

引用本文的文献

[1]
Recent advances in universal chimeric antigen receptor T cell therapy.

J Hematol Oncol. 2025-8-29

[2]
Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond.

Cell Mol Immunol. 2025-6-6

[3]
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.

Front Immunol. 2025-5-21

[4]
A rare germline mutation reverses the suppressive effect of thereby promoting lung adenocarcinoma development and tumorigenesis.

Front Genet. 2025-4-25

[5]
Diverse approaches and sources to derive antitumor T cell for liver cancer: a single-cell sequence based research.

Hepatol Int. 2025-4-7

[6]
tumor cell engineering reverses immune escape to enhance immunotherapy effect.

Acta Pharm Sin B. 2025-1

[7]
Exploring the therapeutic efficacy difference in claudin18.2-targeted cell therapy revealed by single-cell sequencing.

iScience. 2025-1-7

[8]
Precision epitope editing: A path to advanced immunotherapies.

Cell Insight. 2024-12-24

[9]
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

J Immunother Cancer. 2025-1-20

[10]
As new cell and gene therapies emerge from academia, we must RISE to the opportunity.

Nat Biotechnol. 2025-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索